Document:

Exhibit
4.1

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR
PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT
TO PURCHASE STOCK

 

	Corporation:	AUGMEDIX,
    INC., a Delaware corporation
	Number
    of Shares:	1,852
    (subject to Section 1.6)
	Class
    of Stock:	Series
    A Preferred
	Warrant
    Price:	$4.05
    per share
	Issue
    Date:	June
    11, 2015
	Expiration
    Date:	June
    11, 2025 (Subject to Section 4.1)

 

THIS
WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable consideration, the receipt of which
is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase
the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of AUGMEDIX, INC. (the “Company”)
at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions
and upon the terms and conditions set forth in this Warrant.

 

ARTICLE
1

EXERCISE

 

1.1
Method of Exercise. Holder may exercise this Warrant from time to time for all or any part of the unexercised Shares by
delivering a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the
Company (or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the Company
a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate
Warrant Price for the Shares being purchased. Notwithstanding any other provision hereof, if an exercise of any portion of this
Warrant is to be made in connection with a public offering or an Acquisition (as defined below), such exercise may at the election
of the Holder be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be
effective until immediately prior to the closing of such transaction.

 

1.2
Intentionally Omitted.

 

1.3
Delivery of Certificate and New Warrant. Within thirty (30) days after Holder exercises this Warrant and the Company receives
payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this
Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired.

 

1.4
Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, upon delivery of an affidavit and indemnity
agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

 

    Page 1

     

    

 

1.5 Acquisition of the Company.

 

1.5.1 “Acquisition.”
For the purpose of this Warrant, “Acquisition” means (a) any sale, license, or other disposition of all or
substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation,
merger, sale of the voting securities of the Company or other transaction or series of related transactions where the holders
of the Company’s securities before the transaction or series of related transactions beneficially own less than fifty percent
(50%) of the outstanding voting securities of the surviving entity after the transaction or series of related
transactions.

 

1.5.2
Treatment of Warrant in the Event of an Acquisition. The Company shall give Holder written notice at least ten (10) business
days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer
of the Company, (ii) successor or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume
this Warrant as a part of the Acquisition.

 

(a)
If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as would
be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding
on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and the Warrant
Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions
hereof.

 

(b)
If the Acquirer refuses to assume this Warrant in connection with the Acquisition, the Company shall give Holder an additional
written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any
other provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified in this
Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant,
then this Warrant will terminate immediately prior to the closing of the Acquisition. Notwithstanding any other provision of this
Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection
with an Excluded Acquisition (as defined below), then effective as of the date that is ten (10) days prior to the closing of such
Acquisition, the Holder shall have the option to elect to put this Warrant to the Company in exchange for payment to the Holder
in an amount equal to (a) the number of Shares then subject to this Warrant multiplied by (b) the difference between the Acquisition
consideration payable in respect of one Share in connection with the Acquisition (with such determination to be made by the mutual
agreement of the Company and Holder) and the Warrant Price. As used herein, an “Excluded Acquisition” means, an Acquisition
where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash
and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the
Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may
be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or
an effective registration statement under the Act.

 

1.6 Number
of Shares. Upon Comerica Bank making the first Growth Capital Advance to the Company pursuant to that certain Loan and
Security Agreement by and between Comerica Bank and the Company dated as of May 11, 2015, the Number of Shares for which this
Warrant shall be exercisable shall be automatically increased to 5,556.

 

    Page 2

     

    

 

ARTICLE
2

ADJUSTMENTS
TO THE SHARES

 

2.1 Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or other
securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this
Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to
which Holder would have been entitled had Holder owned the Shares issuable upon exercise of this Warrant as of the date the
dividend or subdivision occurred.

 

2.2 Reclassification,
Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of
the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to
receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have
received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution,
or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company
of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation
upon the closing of a registered public offering of the Company’s common stock. The Company or its successor shall promptly
issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which
shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without
limitation, adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant
and expiration date. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges,
substitutions, or other events.

 

2.3 Adjustments
for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification, reverse split or
otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the outstanding Shares
are split or multiplied, by reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be
proportionately decreased.

 

2.4 Adjustments
for Diluting Issuances. In the event of the issuance (a “Diluting Issuance”) by the Company, after the Issue
Date of this Warrant, of securities at a price per share less than the Warrant Price, then the number of shares of common
stock issuable upon conversion of the Shares shall be adjusted in accordance with those provisions of the Company’s
Certificate of Incorporation, a copy of which is attached hereto as Exhibit A, which apply to Diluting Issuances as if
the Shares were outstanding on the date of such Diluting Issuance. The provisions set forth for the Shares in the Company’s
Certificate of Incorporation relating to the above in effect as of the Issue Date may not be amended, modified or waived,
without the prior written consent of Holder unless such amendment, modification or waiver affects the rights associated with
the Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares
of the same series and class as the Shares granted to the Holder. Under no circumstances shall the aggregate Warrant Price
payable by the Holder upon exercise of this Warrant increase as a result of any adjustment arising from a Diluting
Issuance.

 

    Page 3

     

    

 

2.5 No
Impairment. The Company shall not, by amendment of its Articles or Certificate of Incorporation or Bylaws or through a
reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and
in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against dilution
or other impairment; provided however, that (a) any amendment to the Certificate of Incorporation, reorganization, transfer
of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action that affects all
holders of the outstanding Shares (and is not limited in its effect to the Shares that are subject to this Warrant), and (b)
any Acquisition, shall not be a breach or violation of the provisions of this Section 2.5.

 

2.6
Certificate as to Adjustments. Upon each adjustment of the Warrant Price or number of Shares, the Company at its expense
shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth
such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate
setting forth the Warrant Price and number of Shares in effect upon the date thereof and the series of adjustments leading to
such Warrant Price and number of Shares.

 

2.7
Limitations on Liability. Nothing contained in this Warrant shall be construed as imposing any liabilities on Holder to
purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company.

 

2.8
Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be
issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant,
the Company shall eliminate such fractional share interest by paying Holder an amount in cash computed by multiplying the fractional
interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share.

 

ARTICLE
3

REPRESENTATIONS
AND COVENANTS OF THE COMPANY

 

3.1
Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows:

 

3.1.1
The initial Warrant Price referenced on the first page of this Warrant is not greater than the fair market value of the Shares
as of the date of this Warrant as determined by the Company to the best of its knowledge and in good faith.

 

3.1.2
This Warrant is and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, duly authorized
and validly issued. All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all
securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid
and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws.

 

3.1.3
The Company’s capitalization table delivered to Holder as of the Issue Date is true and complete as of the Issue Date.

 

    Page 4

     

    

 

3.2
Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon its stock,
whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription
pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights;
(c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation,
or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection
with each such event, the Company shall give Holder (1) at least ten (10) business days prior written notice of the date on which
a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of
stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b)
above; and (2) in the case of the matters referred to in (c) and (d) above at least ten (10) business days prior written notice
of the date when the same will take place (and specifying the date on which the holders of stock will be entitled to exchange
their stock for securities or other property deliverable upon the occurrence of such event). Upon request, the Company shall provide
Holder with such information reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares
in the case of matters referred to (a), (b), (c) and (d) herein above.

 

3.3
Information Rights. So long as the Holder holds this Warrant and/or any of the Shares, the Company shall deliver to the
Holder (a) promptly after mailing, copies of all communications, information and/or communiqués to the shareholders of
the Company, (b) within one hundred eighty (180) days after the end of each fiscal year of the Company, the annual audited or
CPA reviewed financial statements of the Company certified by independent public accountants of recognized standing and (c) within
forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited
financial statements. In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant
and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its
business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or any
agreement with any holder of the class of Shares.

 

3.4
Registration Under the Act. The Company agrees that the Shares or, if the Shares are convertible into common stock of the
Company, such common stock, shall be deemed “Registrable Securities” or otherwise entitled to “piggy back”
registration rights for registrations initiated by either the Company or a stockholder in accordance with the terms of the that
certain Investors’ Rights Agreement by and among the Company, the investors listed on Schedule A thereto and the stockholders
of the Company listed on Schedule B thereto dated as of December 23, 2014, as may be amended from time to time (the “Agreement”),
a copy of which is attached hereto as Exhibit B. The Company agrees that no amendments will be made to the Agreement which
would impact Holder’s registration rights under this provision in a materially different, adverse manner than any other holders
of registration rights under the Agreement. Holder shall be deemed to be a party to the Agreement solely for the purposes of the
above-mentioned registration rights and any sections related thereto, and for purposes of the market lockup and standoff provision
described in Section 4.5 below.

 

ARTICLE
4

INVESTMENT
REPRESENTATIONS AND COVENANTS OF HOLDER

 

With
respect to the acquisition of this Warrant and any of the Shares, Holder hereby represents and warrants to, and agrees with, the
Company as follows:

 

4.1 Purchase
Entirely for Own Account. This Warrant is issued to Holder in reliance upon Holder’s representation to the Company that
this Warrant and the Shares will be acquired for investment for Holder’s, or its affiliate’s, own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof other than to an affiliate, and that Holder
has no present intention of selling, granting any participation in, or otherwise distributing the same (other than to an
affiliate of Holder who agrees to be similarly bound by these representations and covenants and the other terms of this
Warrant). By executing this Warrant, Holder further represents that Holder does not have any contract, undertaking, agreement
or arrangement with any person (other than to an affiliate of Holder who  agrees to be similarly bound by these
representations and covenants and the other terms of this Warrant), to sell, transfer or grant participations to such person
or to any third person with respect to any of the Shares.

 

    Page 5

     

    

 

4.2
Reliance upon Holder’s Representations. Holder understands that this Warrant and the Shares are not registered under the
Securities Act of 1933, as amended (the “Act”) on the ground that the issuance of such securities is exempt from registration
under the Act, and that the Company’s reliance on such exemption is predicated on Holder’s representations set forth herein.

 

4.3
Accredited Investor Status. Holder is an “accredited investor” as defined in Regulation D promulgated under the
Act and the rules and regulations promulgated thereunder.

 

4.4
Restricted Securities. Holder understands that this Warrant and the Shares are “restricted securities” under
the federal and state securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such federal securities laws and applicable regulations such securities may be resold without registration
under the Act only in certain limited circumstances.

 

4.5
Market Standoff Agreement. Holder agrees to be bound by the market lockup and standoff provisions now contained in Section
3.11 of the Agreement, as such market lockup provisions may be amended from time to time, which are hereby incorporated herein
by this reference.

 

ARTICLE
5

MISCELLANEOUS

 

5.1
Term; Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or
before the Expiration Date set forth above; provided, however, that if the Company completes its initial public offering
within the one-year period immediately prior to the Expiration Date, the Expiration Date shall automatically be extended until
the first anniversary of the effective date of the Company’s initial public offering. The Company agrees that Holder may terminate
this Warrant, upon notice to the Company, at any time in its sole discretion.

 

5.2
Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares,
if any) shall be imprinted with a legend in substantially the following form:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THE ACT, AND ANY APPLICABLE STATE SECURITIES LAWS.

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A 180 DAY MARKET STAND-OFF RESTRICTION AS SET FORTH IN A CERTAIN AGREEMENT
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.
AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE INITIAL PUBLIC
OFFERING OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES.

 

    Page 6

     

    

 

5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole
or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company
shall not require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel or
investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”), or
any other affiliate of Bank that is an “accredited investor” as that term is defined in Regulation D promulgated under
the Act (“Bank Affiliate”).

 

5.4
Transfer Procedure. After receipt of the executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures
Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of Section
4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this Warrant being
transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant
to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all
or part of this Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery
of any other instrument to the Company, and such affiliate shall then be entitled to all the rights of Holder under this Warrant
and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant
is issued in the name of the affiliate that exercises this Warrant. The terms and conditions of this Warrant shall inure to the
benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns.

 

5.5
Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered
and effective when: (i) given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a
nationally recognized overnight courier service (such as, but not limited to, Federal Express, DHL or UPS), fee prepaid, or (ii)
on the date sent by email or facsimile if sent during normal business hours of the recipient, and on the next business day if
sent after normal business hours of the recipient. Such communications must be sent to the respective parties at the address or
facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such
Holder from time to time. Effective upon the receipt of executed Warrant and initial transfer described in Article 5.4 above,
all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection
with a transfer or otherwise:

 

Comerica
Ventures Incorporated

Attn: Warrant Administrator

1717
Main Street, 5th Floor, MC 6406

Dallas,
Texas 75201

Facsimile
No. [*]

 

    Page 7

     

    

 

All
notices to the Company shall be addressed as follows:

 

AUGMEDIX,
INC.

1161
Mission Street, Suite 210

San Francisco, CA 94103

Attn:
Ian Shakil, CEO

FAX:
(       )                        

 

5.6
Amendments; Waiver. This Warrant and any term hereof may be amended, modified or supplemented by an agreement in writing
signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective unless
explicitly set forth in writing and signed by the party so waiving. No failure to exercise, or delay in exercising, any rights,
remedy, power or privilege arising from this Warrant shall operate or be construed as a waiver thereof, nor shall any single or
partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise
of any other right, remedy, power or privilege.

 

5.7
Cumulative Remedies. The rights and remedies provided in this Warrant are cumulative and are not exclusive of, and are
in addition and not in substitution for, any other rights or remedies available at law, in equity or otherwise.

 

5.8
No Strict Construction. This Warrant shall be construed without regard to any presumption or rule requiring construction
or interpretation against the party drafting an instrument or causing any instrument to be drafted.

 

5.9
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California,
without giving effect to its principles regarding conflicts of law,

 

5.10
Confidentiality. The Company hereby agrees to keep the terms and conditions of this Warrant confidential. Notwithstanding
the foregoing confidentiality obligation, the Company may disclose information relating to this Warrant as required by law, rule,
regulation, court order or other legal authority, provided that (i) the Company has given Holder at least ten (10) days’ notice
of such required disclosure, and (ii) the Company only discloses information that is required, in the opinion of counsel reasonably
satisfactory to Holder, to be disclosed.

 

	AUGMEDIX, INC.	 
	 	 	 
	By:	/s/
    Ian Shakil	 
	Name: 
    	Ian
    Shakil	 
	Title:	CEO	 

 

    Page 8

     

    

 

APPENDIX I

NOTICE
OF EXERCISE

 

1.
The undersigned hereby elects to purchase _______________ shares of the  _______________ stock of AUGMEDIX, INC. pursuant to the terms
of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full.

 

2.
Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is
specified below:

 

Comerica
Ventures Incorporated

Attn:
Warrant Administrator

1717
Main Street, 5th Floor, MC 6406

Dallas,
Texas 75201

Facsimile
No. [*]

 

3.
The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and
not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

	COMERICA
    VENTURES INCORPORATED or 	 
	Assignee	 
	 	 
	 	 
	(Signature)	 
	 	 
	 	 
	(Name
    and Title)	 
	 	 
	 	 
	(Date)	 

 

    Page 9

     

    

 

Exhibit
A

 

Anti-Dilution
Provisions

 

Certificate
of Incorporation (including all amendments thereto) – ATTACHED HERETO

 

    Exhibit A
 Page 1

     

    

 

Exhibit
B

 

Registration
Rights

 

Investors
Rights Agreement (including all amendments thereto) – ATTACHED HERETO

 

 

 

Exhibit B

Page 1Exhibit 4.2

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR
PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT
TO PURCHASE STOCK

 

	Corporation:	AUGMEDIX,
    INC., a Delaware corporation
	Number
    of Shares:	See
    Section 1.6
	Class
    of Stock:	Series
    A-2 Preferred
	Warrant
    Price:	$6.2326
    per share
	Issue
    Date:	July
    28, 2017
	Expiration
    Date:	July
    28, 2027 (Subject to Section 4.1)

 

THIS
WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable consideration, the receipt of which
is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase
the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of AUGMEDIX, INC. (the
“Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject
to the provisions and upon the terms and conditions set forth in this Warrant.

 

ARTICLE
1

EXERCISE

 

1.1
Method of Exercise. Holder may exercise this Warrant from time to time for all or any part of the unexercised Shares by
delivering a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the
Company (or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the Company
a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate
Warrant Price for the Shares being purchased. Notwithstanding any other provision hereof, if an exercise of any portion of this
Warrant is to be made in connection with a public offering or an Acquisition (as defined below), such exercise may at the election
of the Holder be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be
effective until immediately prior to the closing of such transaction.

 

1.2
Intentionally Omitted.

 

1.3
Delivery of Certificate and New Warrant. Within thirty (30) days after Holder exercises this Warrant and the Company receives
payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this
Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired.

 

1.4
Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, upon delivery of an affidavit and indemnity
agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

 

    Page 1

     

    

 

1.5
Acquisition of the Company.

 

1.5.1
“Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any sale, license, or other
disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization,
consolidation, merger, sale of the voting securities of the Company or other transaction or series of related transactions where
the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than
fifty percent (50%) of the outstanding voting securities of the surviving entity after the transaction or series of related transactions.

 

1.5.2
Treatment of Warrant in the Event of an Acquisition. The Company shall give Holder written notice at least ten (10) business
days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer
of the Company, (ii) successor or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume
this Warrant as a part of the Acquisition.

 

(a)
If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as would
be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding
on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and the Warrant
Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions
hereof.

 

(b)
If the Acquirer refuses to assume this Warrant in connection with the Acquisition, the Company shall give Holder an additional
written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any
other provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified in this
Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant,
then this Warrant will terminate immediately prior to the closing of the Acquisition. Notwithstanding any other provision of this
Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection
with an Excluded Acquisition (as defined below), then effective as of the date that is ten (10) days prior to the closing of such
Acquisition, the Holder shall have the option to elect to put this Warrant to the Company in exchange for payment to the Holder
in an amount equal to (a) the number of Shares then subject to this Warrant multiplied by (b) the difference between the Acquisition
consideration payable in respect of one Share in connection with the Acquisition (with such determination to be made by the mutual
agreement of the Company and Holder) and the Warrant Price. As used herein, an “Excluded Acquisition” means, an Acquisition
where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash
and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the
Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may
be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or
an effective registration statement under the Act.

 

1.6
Number of Shares. Upon Comerica Bank making Growth Capital Advances to the Company in excess of Three Million Five Hundred
Thousand Dollars ($3,500,000) pursuant to that certain Loan and Security Agreement by and between Comerica Bank and the Company
dated as of May11, 2015 (as amended from time to time including by that certain First Amendment to Loan and Security Agreement
dated as of February 14, 2017, that certain Second Amendment to Loan and Security Agreement dated as of April 11, 2017 and that
certain Third Amendment to Loan and Security Agreement dated as of the date hereof) the Number of Shares for which this Warrant
shall be exercisable shall be set at 1,564 Shares. For the avoidance of doubt, this Warrant shall not be exercisable until such
time.

 

    Page 2

     

    

 

ARTICLE
2

ADJUSTMENTS
TO THE SHARES

 

2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or
other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this
Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which
Holder would have been entitled had Holder owned the Shares issuable upon exercise of this Warrant as of the date the dividend
or subdivision occurred.

 

2.2
Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results
in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be
entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would
have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution,
or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company
of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation
upon the closing of a registered public offering of the Company’s common stock. The Company or its successor shall promptly
issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall
be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation,
adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant and expiration
date. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other
events.

 

2.3
Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification, reverse
split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the outstanding Shares
are split or multiplied, by reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately
decreased.

 

2.4
Adjustments for Diluting Issuances. In the event of the issuance (a “Diluting Issuance”) by the Company, after
the Issue Date of this Warrant, of securities at a price per share less than the Warrant Price, then the number of shares of common
stock issuable upon conversion of the Shares shall be adjusted in accordance with those provisions of the Company’s Certificate
of Incorporation, a copy of which is attached hereto as Exhibit A, which apply to Diluting Issuances as if the Shares were
outstanding on the date of such Diluting Issuance. The provisions set forth for the Shares in the Company’s Certificate
of Incorporation relating to the above in effect as of the Issue Date may not be amended, modified or waived, without the prior
written consent of Holder unless such amendment, modification or waiver affects the rights associated with the Shares in the same
manner as such amendment, modification or waiver affects the rights associated with all other shares of the same series and class
as the Shares granted to the Holder. Under no circumstances shall the aggregate Warrant Price payable by the Holder upon exercise
of this Warrant increase as a result of any adjustment arising from a Diluting Issuance.

 

    Page 3

     

    

 

2.5
No Impairment. The Company shall not, by amendment of its Articles or Certificate of Incorporation or Bylaws or through
a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant
by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking
all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against dilution or other
impairment; provided however, that (a) any amendment to the Certificate of Incorporation, reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action that affects all holders of the
outstanding Shares (and is not limited in its effect to the Shares that are subject to this Warrant), and (b) any Acquisition,
shall not be a breach or violation of the provisions of this Section 2.5.

 

2.6
Certificate as to Adjustments. Upon each adjustment of the Warrant Price or number of Shares, the Company at its expense
shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth
such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate
setting forth the Warrant Price and number of Shares in effect upon the date thereof and the series of adjustments leading to
such Warrant Price and number of Shares.

 

2.7
Limitations on Liability. Nothing contained in this Warrant shall be construed as imposing any liabilities on Holder to
purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company.

 

2.8
Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be
issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant,
the Company shall eliminate such fractional share interest by paying Holder an amount in cash computed by multiplying the fractional
interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share.

 

ARTICLE
3

REPRESENTATIONS
AND COVENANTS OF THE COMPANY

 

3.1
Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows:

 

3.1.1
The initial Warrant Price referenced on the first page of this Warrant is not greater than the fair market value of the Shares
as of the date of this Warrant as determined by the Company to the best of its knowledge and in good faith.

 

3.1.2
This Warrant is and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, duly authorized
and validly issued. All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all
securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid
and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws.

 

3.1.3
The Company’s capitalization table delivered to Holder as of the Issue Date is true and complete as of the Issue Date.

 

 

    Page 4

     

    

 

3.2 Notice of Certain Events.
If the Company proposes at any time (a) to declare any dividend or distribution upon its stock, whether in cash, property,
stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of
any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification
or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey
all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company
shall give Holder (1) at least ten (10) business days prior written notice of the date on which a record will be taken for such
dividend, distribution, or subscription rights (and specifying the date on which the holders of stock will be entitled thereto)
or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and (2) in the case of
the matters referred to in (c) and (d) above at least ten (10) business days prior written notice of the date when the same will
take place (and specifying the date on which the holders of stock will be entitled to exchange their stock for securities or other
property deliverable upon the occurrence of such event). Upon request, the Company shall provide Holder with such information
reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares in the case of matters referred
to (a), (b), (c) and (d) herein above.

 

3.3
Information Rights. So long as the Holder holds this Warrant and/or any of the Shares, the Company shall deliver to the
Holder (a) promptly after mailing, copies of all communications, information and/or communiqués to the shareholders of
the Company, (b) within one hundred eighty (180) days after the end of each fiscal year of the Company, the annual audited or
CPA reviewed financial statements of the Company certified by independent public accountants of recognized standing and (c) within
forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited
financial statements. In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant
and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its
business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or any
agreement with any holder of the class of Shares.

 

3.4
Registration Under the Act. The Company agrees that the Shares or, if the Shares are convertible into common stock of the
Company, such common stock, shall be deemed “Registrable Securities” or otherwise entitled to “piggy back”
registration rights for registrations initiated by either the Company or a stockholder in accordance with the terms of the that
certain Amended and Restated Investors’ Rights Agreement by and among the Company, the investors listed on Schedule A thereto
and the stockholders of the Company listed on Schedule B thereto dated as of October 6, 2015, as may be amended from time to time
(the “Agreement”), a copy of which is attached hereto as Exhibit B. The Company agrees that no amendments will
be made to the Agreement which would impact Holder’s registration rights under this provision in a materially different,
adverse manner than any other holders of registration rights under the Agreement. Holder shall be deemed to be a party to the
Agreement solely for the purposes of the above-mentioned registration rights and any sections related thereto, and for purposes
of the market lockup and standoff provision described in Section 4.5 below.

 

    Page 5

     

    

  

ARTICLE
4

INVESTMENT
REPRESENTATIONS AND COVENANTS OF HOLDER

 

With
respect to the acquisition of this Warrant and any of the Shares, Holder hereby represents and warrants to, and agrees with, the
Company as follows:

 

4.1
Purchase Entirely for Own Account. This Warrant is issued to Holder in reliance upon Holder’s representation to the
Company that this Warrant and the Shares will be acquired for investment for Holder’s, or its affiliate’s, own account,
not as a nominee or agent, and not with a view to the resale or distribution of any part thereof other than to an affiliate, and
that Holder has no present intention of selling, granting any participation in, or otherwise distributing the same (other than
to an affiliate of Holder who agrees to be similarly bound by these representations and covenants and the other terms of this
Warrant). By executing this Warrant, Holder further represents that Holder does not have any contract, undertaking, agreement
or arrangement with any person (other than to an affiliate of Holder who agrees to be similarly bound by these representations
and covenants and the other terms of this Warrant), to sell, transfer or grant participations to such person or to any third person
with respect to any of the Shares.

 

4.2
Reliance upon Holder’s Representations. Holder understands that this Warrant and the Shares are not registered under
the Securities Act of 1933, as amended (the “Act”) on the ground that the issuance of such securities is exempt from
registration under the Act, and that the Company’s reliance on such exemption is predicated on Holder’s representations
set forth herein.

 

4.3
Accredited Investor Status. Holder is an “accredited investor” as defined in Regulation D promulgated under
the Act and the rules and regulations promulgated thereunder.

 

4.4
Restricted Securities. Holder understands that this Warrant and the Shares are “restricted securities” under
the federal and state securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such federal securities laws and applicable regulations such securities may be resold without registration
under the Act only in certain limited circumstances.

 

4.5
Market Standoff Agreement. Holder agrees to be bound by the market lockup and standoff provisions now contained in Section
3.11 of the Agreement, as such market lockup provisions may be amended from time to time, which are hereby incorporated herein
by this reference.

 

4.6
No Stockholder Rights. Without limiting any provision of this Warrant, Holder agrees that as a Holder of this Warrant it
will not have any rights (including, but not limited to, voting rights) as a stockholder of the Company with respect to the Shares
issuable hereunder unless and until the exercise of this Warrant and then only with respect to the Shares issued on such exercise.

 

ARTICLE
5

MISCELLANEOUS

 

5.1
Term; Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or
before the Expiration Date set forth above; provided, however, that if the Company completes its initial public offering
within the one-year period immediately prior to the Expiration Date, the Expiration Date shall automatically be extended until
the first anniversary of the effective date of the Company’s initial public offering. The Company agrees that Holder may
terminate this Warrant, upon notice to the Company, at any time in its sole discretion.

 

    Page 6

     

    

 

5.2
Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares,
if any) shall be imprinted with a legend in substantially the following form:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY
BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, OR PURSUANT TO RULE 144 OR AN EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE ACT, AND ANY APPLICABLE STATE SECURITIES LAWS.

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A 180 DAY MARKET STAND-OFF RESTRICTION AS SET FORTH IN A CERTAIN AGREEMENT
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.
AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE INITIAL PUBLIC
OFFERING OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES.

 

5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole
or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company
shall not require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel
or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”),
or any other affiliate of Bank that is an “accredited investor” as that term is defined in Regulation D promulgated
under the Act (“Bank Affiliate”).

 

5.4
Transfer Procedure. After receipt of the executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures
Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of
Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this Warrant
being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant
to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all
or part of this Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery
of any other instrument to the Company, and such affiliate shall then be entitled to all the rights of Holder under this Warrant
and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant
is issued in the name of the affiliate that exercises this Warrant. The terms and conditions of this Warrant shall inure to the
benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns.

 

    Page 7

     

    

 

5.5 Notices.
All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective
when: (i) given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally
recognized overnight courier service (such as, but not limited to, Federal Express, DHL or UPS), fee prepaid, or (ii) on the
date sent by email or facsimile if sent during normal business hours of the recipient, and on the next business day if sent
after normal business hours of the recipient. Such communications must be sent to the respective parties at the address or
facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or
such Holder from time to time. Effective upon the receipt of executed Warrant and initial transfer described in Article 5.4
above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in
connection with a transfer or otherwise:

 

Comerica
Ventures Incorporated

Attn:
Warrant Administrator

1717 Main Street, 5th Floor, MC 6406

Dallas, Texas 75201

Facsimile
No. [*]

 

All
notices to the Company shall be addressed as follows:

 

AUGMEDIX,
INC.

1161
Mission Street, Suite 210

San Francisco, CA 94103

Attn:
Ian Shakil, CEO

FAX:
(      )                         

 

5.6 Amendments; Waiver. This
Warrant and any term hereof may be amended, modified or supplemented by an agreement in writing signed by each party hereto. No
waiver by the Company or the Holder of any of the provisions hereof shall be effective unless explicitly set forth in writing
and signed by the party so waiving. No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising
from this Warrant shall operate or be construed as a waiver thereof, nor shall any single or partial exercise of any right, remedy,
power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power
or privilege.

 

5.7
Cumulative Remedies. The rights and remedies provided in this Warrant are cumulative and are not exclusive of, and are
in addition and not in substitution for, any other rights or remedies available at law, in equity or otherwise.

 

5.8
No Strict Construction. This Warrant shall be construed without regard to any presumption or rule requiring construction
or interpretation against the party drafting an instrument or causing any instrument to be drafted.

 

5.9
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to its principles regarding conflicts of law.

 

5.10
Confidentiality. The Company hereby agrees to keep the terms and conditions of this Warrant confidential. Notwithstanding
the foregoing confidentiality obligation, the Company may disclose information relating to this Warrant as required by law, rule,
regulation, court order or other legal authority, provided that (i) the Company has given Holder at least ten (10) days’
notice of such required disclosure, and (ii) the Company only discloses information that is required, in the opinion of counsel
reasonably satisfactory to Holder, to be disclosed.

 

    Page 8

     

    

 

	AUGMEDIX, INC.	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

[Signature
Page to Warrant to Purchase Stock]

 

    Page 9

     

    

 

APPENDIX
I

NOTICE
OF EXERCISE 

 

1.
The undersigned hereby elects to purchase                              
shares of the                  
stock of AUGMEDIX, INC. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price
of such shares in full.

 

2.
Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is
specified below:

 

Comerica
Ventures Incorporated

Attn: Warrant Administrator

1717 Main Street, 5th Floor, MC 6406

Dallas, Texas 75201

Facsimile
No. [*]

 

3.
The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and
not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

	COMERICA
    VENTURES INCORPORATED or

Assignee	 
	 	 
	 	 
	(Signature)	 
	 	 
	 	 
	(Name
    and Title)	 
	 	 
	 	 
	(Date)	 

  

    Page 10

     

    

 

Exhibit
A

 

Anti-Dilution
Provisions

 

Certificate
of Incorporation (including all amendments thereto) – ATTACHED HERETO

 

    Exhibit A
 Page 1

     

    

 

Exhibit
B

 

Registration
Rights

 

Investors
Rights Agreement (including all amendments thereto) – ATTACHED HERETO

 

 

 

Exhibit
B

Page 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]